TriSalus Life Sciences (TLSI) Preferred Stock Liabilities (2020 - 2023)

TriSalus Life Sciences' Preferred Stock Liabilities history runs 4 years deep, the most recent figure standing at $12.0 million for Q2 2023.

• On a quarterly basis, Preferred Stock Liabilities fell 95.18% year-over-year to $12.0 million in Q2 2023; TTM through Jun 2023 was $12.0 million, a 95.18% decrease from a year earlier, with the FY2022 full-year figure at $164.0 million, up 2.18% from the prior year.
• Preferred Stock Liabilities slipped to $12.0 million in Q2 2023 per TLSI's latest filing, from $20.2 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $250.0 million in Q2 2022 and bottomed at $12.0 million in Q2 2023.
• The 4-year median for Preferred Stock Liabilities is $250.0 million (2020), against an average of $183.7 million.
• Across the five-year window, Preferred Stock Liabilities rose 2.18% in 2022 and slumped 95.18% in 2023, its largest moves.
• Year by year, Preferred Stock Liabilities stood at $250.0 million in 2020, then plunged by 35.8% to $160.5 million in 2021, then rose by 2.18% to $164.0 million in 2022, then tumbled by 92.66% to $12.0 million in 2023.
• Per Business Quant, the three latest TLSI Preferred Stock Liabilities figures stand at $12.0 million (Q2 2023), $20.2 million (Q1 2023), and $164.0 million (Q4 2022).